Cervical cancer prevention prebiotic device - in this phase II sbir project, glyciome, a women-owned company, is commercializing 'prebiogyn', a prebiotic intravaginal lubricant designed to prevent…

Active Project Grant Awarded Last action

Award ID
R44CA254543
Recipient
Awarding agency
Obligated
$3,323,144

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date 86% complete
Place of performance
Valleyford, WA, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Cervical cancer prevention prebiotic device - in this phase II sbir project, glyciome, a women-owned company, is commercializing 'prebiogyn', a prebiotic intravaginal lubricant designed to prevent bacterial vaginosis (BV), the most common vaginal infection in the world and an established biological risk factor for cervical cancer (CC). There is an urgent need to prevent this cancer (the 4TH most common for women globally), which is causing rising death rates in the US for those in low- resource settings (LRS). Our patent-pending, preservative-free therapeutic device offers a disruptive microecological approach to CC prevention for use by anyone - regardless of their human papillomavirus (HPV) vaccination status - to optimize women's health and reduce public health costs. This is critical in the US, where

Transactions

Action Obligated Date
Amendment $1,244,380
Amendment $0
Amendment $0
Amendment $1,039,382
Original award $1,039,382

Quick answers

Who received award R44CA254543?

R44CA254543 was awarded to Glyciome LLC by National Cancer Institute (National Institutes of Health) on June 17, 2021.

How much is award R44CA254543 worth?

$3,323,144 has been obligated on R44CA254543.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login